Streetbeat News

Regulatory

BTCUSD

XRPUSD

Bitcoin is nearing its all-time high, with analysts predicting a bullish trend due to favorable market conditions, including potential interest rate cuts and increased global liquidity. In contrast, XRP faces uncertainty due to an ongoing SEC appeal against Ripple, which could lead to significant price volatility depending on the outcome.

Portfolio Pulse from Murtuza Merchant

October 21, 2024 | 7:36 pm

NVDA

TSM

Nvidia's stock has reached an all-time high due to strong AI demand, particularly for its GPUs. The company is experiencing high demand for its next-gen Blackwell GPU platform. Nvidia's upcoming earnings report and partnerships, like the one with Aidoc, are key focus areas. However, export restrictions pose potential challenges.

Portfolio Pulse from Vaishali Prayag

October 21, 2024 | 7:10 pm

XRP

Ripple Labs co-founder Chris Larsen has donated nearly $10 million to Kamala Harris' presidential campaign, supporting her vision for the cryptocurrency industry. Despite this, Harris' election odds remain lower than Donald Trump's. The crypto community is divided, with some leaders supporting Trump for his stance on SEC regulation.

Portfolio Pulse from Murtuza Merchant

October 21, 2024 | 6:50 pm

MAPS

Weedmaps, listed as WM Technology Inc. (NASDAQ:MAPS), faces a class action lawsuit from investors following SEC fines for misleading performance metrics. The SEC charged Weedmaps with inflating user metrics, leading to fines for former executives. The lawsuit expands to include additional executives. NASDAQ warned Weedmaps about its stock price falling below $1.00, risking delisting.

Portfolio Pulse from Juan Spínelli

October 21, 2024 | 6:29 pm

SPY

Neel Kashkari, President of the Minneapolis Federal Reserve, stated that the primary role of monetary policy in reducing inflation was likely in anchoring inflation expectations rather than reducing demand.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 6:25 pm

LLY

Eli Lilly has filed lawsuits against several vendors for selling unauthorized versions of its weight-loss drug, Zepbound, containing tirzepatide. Despite resolving a previous shortage, Eli Lilly is taking legal action to stop counterfeit sales and is seeking damages.

Portfolio Pulse from Vandana Singh

October 21, 2024 | 6:17 pm

SPY

Neel Kashkari from the Federal Reserve discussed the impact of immigration policy on labor market readings and stated that tariffs likely cause a one-time price change rather than ongoing inflation. He emphasized the importance of avoiding a recession and noted signs of labor market weakening, which led to a 50 basis point rate cut. Future rate policy will depend on comprehensive data analysis.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 6:04 pm

SPY

Neel Kashkari from the Federal Reserve suggests that an increase in the budget deficit could lead to higher interest rates. He also comments on the limited legitimate use of cryptocurrencies, implying most transactions are related to illegal activities.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 5:46 pm

SPY

Neel Kashkari from the Federal Reserve indicated that an increase in the budget deficit could lead to higher interest rates. This statement suggests potential impacts on the broader market, including ETFs like SPY, which track the S&P 500.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 5:43 pm

BNTX

The FDA has imposed a partial clinical hold on BioNTech's Phase 3 trial for a lung cancer treatment due to varying outcomes in patient subgroups. Current patients will continue treatment, but new enrollments are paused. BioNTech's stock saw a slight decline following the news.

Portfolio Pulse from Vandana Singh

October 21, 2024 | 4:51 pm